Anbio Biotechnology
NNNN- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001982708
No open-market purchases or sales by Anbio Biotechnology insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $985.2K in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Anbio Biotechnology changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 0 | 3 | +3 |
| Shares | 0 | 66.4K | +66.4K |
| Value | $0 | $495.5K | +$495.5K |
New holders (3)
Institutions that held Anbio Biotechnology at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 43,629 | $325.5K | 0.00% |
| Geode Capital Management, LLC | 17,060 | $127.3K | 0.00% |
| UBS Group AG | 5,738 | $42.8K | 0.00% |
Sold out (0)
Institutions that held Anbio Biotechnology at the end of Q4 2024 and filed for Q1 2025 without it.
None.